The Pharmaceutical Journal
Vol 280 No 7502 p590
17 May 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Further data required before varenicline can be regarded as first-choice for quitters

Varenicline (Champix) should not be regarded as the first-line choice for smoking cessation therapy until further data are available and reports of depression and suicidal ideation have been further reviewed, according to the latest Drug and Therapeutics Bulletin (May 2008).

“Use of the drug should follow discussion with the patient of current safety concerns and treatment should be combined with regular advice and support from a healthcare professional,” it says (2008;46:33).